AKT1 and renal cell carcinoma: Zhong et al. [16] proved that eupatilin, a novel therapeutic agent in the treatment of renal cell carcinoma, promotes ROS-mediated MAPK activation, inhibits the PI3K/AKT cascade, and triggers programmed cell death in RCC cells.